[go: up one dir, main page]

HRP20211824T1 - Modulators of complement activity - Google Patents

Modulators of complement activity Download PDF

Info

Publication number
HRP20211824T1
HRP20211824T1 HRP20211824TT HRP20211824T HRP20211824T1 HR P20211824 T1 HRP20211824 T1 HR P20211824T1 HR P20211824T T HRP20211824T T HR P20211824TT HR P20211824 T HRP20211824 T HR P20211824T HR P20211824 T1 HRP20211824 T1 HR P20211824T1
Authority
HR
Croatia
Prior art keywords
polypeptide
use according
subject
hemolysis
eculizumab
Prior art date
Application number
HRP20211824TT
Other languages
Croatian (hr)
Inventor
Michelle Denise HOARTY
Ketki Ashok DHAMNASKAR
Daniel Elbaum
Kristopher JOSEPHSON
Kelley Cronin LARSON
Zhong MA
Nathan Ezekiel Nims
Alonso RICARDO
Kathleen Seyb
Guo-Qing Tang
Douglas A. Treco
Zhaolin Wang
Ping Ye
Hong Zheng
Sarah Jacqueline PERLMUTTER
Original Assignee
Ra Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/035473 external-priority patent/WO2015191951A2/en
Application filed by Ra Pharmaceuticals, Inc. filed Critical Ra Pharmaceuticals, Inc.
Publication of HRP20211824T1 publication Critical patent/HRP20211824T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)

Claims (10)

1. Polipeptid koji se sastoji od SEQ ID NO: 194 ili SEQ ID NO: 184 za uporabu u postupku liječenja poremećaja povezanog s C5 komplementom, postupak koji se sastoji od primjene polipeptida u dozi od oko 0.1 mg/kg do oko 10 mg /kg pri čemu je hemoliza u subjektu smanjena za najmanje 50% u odnosu na razine hemolize koje su prethodno uočene kod navedenog subjekta.1. A polypeptide comprising SEQ ID NO: 194 or SEQ ID NO: 184 for use in the treatment of a disorder associated with C5 complement, the procedure comprising administration of the polypeptide at a dose of about 0.1 mg/kg to about 10 mg/kg wherein hemolysis in the subject is reduced by at least 50% compared to levels of hemolysis previously observed in said subject. 2. Polipeptid za uporabu prema zahtjevu 1, naznačen time što se navedeni polipeptid daje navedenom subjektu u dozi od oko 0.3 mg/kg do oko 3 mg/kg.2. Polypeptide for use according to claim 1, characterized in that said polypeptide is administered to said subject in a dose of about 0.3 mg/kg to about 3 mg/kg. 3. Polipeptid za uporabu prema zahtjevu 2, naznačen time što se navedeni polipeptid daje navedenom subjektu u dozi od oko 0.3 mg/kg.3. Polypeptide for use according to claim 2, characterized in that said polypeptide is given to said subject in a dose of about 0.3 mg/kg. 4. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-3, naznačen time što se navedena primjena provodi svakodnevno.4. Polypeptide for use according to any one of claims 1-3, characterized in that said application is carried out daily. 5. Polipeptid za uporabu prema zahtjevu 4, naznačen time što se navedena primjena provodi sedam dana.5. Polypeptide for use according to claim 4, characterized in that said application is carried out for seven days. 6. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-5, naznačen time što je poremećaj povezan s C5-komplementom paroksizmalna noćna hemoglobinurija.6. The polypeptide for use according to any one of claims 1-5, characterized in that the C5-complement related disorder is paroxysmal nocturnal hemoglobinuria. 7. Polipeptid za uporabu prema zahtjevu 6, naznačen time što je navedeni subjekt prethodno liječen ECULIZUMAB-om.7. Polypeptide for use according to claim 6, characterized in that said subject has been previously treated with ECULIZUMAB. 8. Polipeptid za uporabu prema zahtjevu 6, naznačen time što navedeni subjekt također prima tretman s ECULIZUMAB-om.8. The polypeptide for use according to claim 6, wherein said subject is also receiving treatment with ECULIZUMAB. 9. Polipeptid za uporabu prema zahtjevu 7 ili 8, naznačen time što je liječenje ECULIZUMAB-om neučinkovito.9. Polypeptide for use according to claim 7 or 8, characterized in that treatment with ECULIZUMAB is ineffective. 10. Polipeptid za uporabu prema bilo kojem od zahtjeva 1-9, naznačen time što je hemoliza kod subjekta smanjena za najmanje 90% u odnosu na razine hemolize koje su prethodno uočene kod navedenog subjekta.10. The polypeptide for use according to any one of claims 1-9, characterized in that hemolysis in the subject is reduced by at least 90% relative to levels of hemolysis previously observed in said subject.
HRP20211824TT 2015-01-28 2016-01-28 Modulators of complement activity HRP20211824T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562108772P 2015-01-28 2015-01-28
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
US201562185298P 2015-06-26 2015-06-26
EP16744125.2A EP3250230B9 (en) 2015-01-28 2016-01-28 Modulators of complement activity
PCT/US2016/015412 WO2016123371A1 (en) 2015-01-28 2016-01-28 Modulators of complement activity

Publications (1)

Publication Number Publication Date
HRP20211824T1 true HRP20211824T1 (en) 2022-03-04

Family

ID=56544343

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211824TT HRP20211824T1 (en) 2015-01-28 2016-01-28 Modulators of complement activity

Country Status (14)

Country Link
US (6) US9937222B2 (en)
EP (2) EP3988110A1 (en)
JP (2) JP6640229B2 (en)
CY (1) CY1124761T1 (en)
ES (1) ES2900998T3 (en)
HR (1) HRP20211824T1 (en)
HU (1) HUE056613T2 (en)
LT (1) LT3250230T (en)
PL (1) PL3250230T3 (en)
PT (1) PT3250230T (en)
RS (1) RS62630B9 (en)
SI (1) SI3250230T1 (en)
SM (1) SMT202100688T1 (en)
WO (1) WO2016123371A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102503319B1 (en) 2014-06-12 2023-02-28 라 파마슈티컬스 인코포레이티드 Modulation of complement activity
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
RS64067B1 (en) * 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulators of complement activity
WO2018106859A1 (en) * 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2018193122A1 (en) * 2017-04-21 2018-10-25 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
US20210113658A1 (en) * 2017-04-21 2021-04-22 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of cicatrising eye inflammatory disorders
US20220133841A1 (en) 2018-10-22 2022-05-05 Ra Pharmaceuticals, Inc. Neurological disease treatment with zilucoplan
CN113966224A (en) 2019-06-04 2022-01-21 Ra制药公司 Treatment of inflammatory diseases with complement inhibitors
JP6773930B1 (en) 2019-08-09 2020-10-21 住友化学株式会社 Manufacturing method of liquid crystal polyester resin molded product, liquid crystal polyester resin pellet, and liquid crystal polyester resin pellet
CN114423445A (en) 2019-09-12 2022-04-29 Ra制药公司 Use of Complement Inhibitors to Treat Neurological Disorders
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
KR0185192B1 (en) 1989-10-05 1999-04-01 제임스 더블유. 데이비 Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
AU684510B2 (en) 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
PT710243E (en) 1993-06-29 2000-11-30 Ferring Bv IMPROVED SYNTHESIS OF CYCLIC PEPTIDOS.
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69739163D1 (en) 1996-10-17 2009-01-22 Mitsubishi Chem Corp Molecule that combines genotype and phenotype and its applications
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6258558B1 (en) 1997-01-21 2001-07-10 The General Hospital Corporation Method for selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP3614866B2 (en) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド Artificial antibody polypeptide
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
NZ509410A (en) 1998-08-07 2003-08-29 Emisphere Tech Inc Compounds and compositions for delivering active agents
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
ES2387275T3 (en) 2003-05-15 2012-09-19 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
US7348401B2 (en) 2003-09-10 2008-03-25 Innate Biotech, Inc. Peptides that inhibit complement activation
EP1706098A4 (en) 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc Micellar systems useful for delivery of lipophilic or hydrophobic compounds
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
PT1844337E (en) 2005-01-24 2014-04-03 Pepscan Systems Bv Binding compounds, immunogenic compounds and peptidomimetics
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
ES2548700T3 (en) 2005-05-26 2015-10-20 The Regents Of The University Of Colorado, A Body Corporate Inhibition of the alternative complement pathway for the treatment of traumatic brain injury, spinal cord injury and related conditions
JP5198261B2 (en) 2005-06-06 2013-05-15 カムルス エービー GLP-1 analog preparation
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
BRPI0708909B8 (en) 2006-03-15 2021-05-25 Alexion Pharma Inc use of an antibody that binds to c5 to treat a patient suffering from paroxysmal nocturnal hemoglobinuria
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
DK2698166T3 (en) 2006-10-10 2015-12-21 Regenesance B V KOMPLEMENTÆRHÆMNING FOR BETTER nerves GENERATION
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
EP2121016A1 (en) 2007-03-06 2009-11-25 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
EP2129681A2 (en) 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
RU2009144142A (en) 2007-04-30 2011-06-10 Алькон Рисерч, Лтд. (Us) TREATMENT OF AGE YELLOW SPOT DEGENERATION WITH APPLICATION OF INHIBITORS OF FACTOR D OF COMPLEMENT
MX2009013082A (en) 2007-06-07 2010-01-15 Genentech Inc C3b antibodies and methods for the prevention and treatment of complement- associated disorders.
US20110142837A1 (en) 2007-07-20 2011-06-16 Trustees Of The University Of Pennsylvania Method Of Treating Acute Respiratory Distress Syndrome
KR20100094453A (en) 2007-10-02 2010-08-26 포텐시아 팔마큐티칼스, 인크. Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010014830A2 (en) 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
WO2010025510A1 (en) 2008-09-03 2010-03-11 Xenome Ltd Libraries of peptide conjugates and methods for making them
HRP20230167T1 (en) 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2488203B1 (en) 2009-10-16 2016-12-07 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
CN102958535A (en) 2009-11-05 2013-03-06 亚力史剑桥公司 Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
AU2010338387B2 (en) 2009-12-16 2014-10-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
WO2011106635A1 (en) 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CN110075294A (en) 2011-04-08 2019-08-02 莱斯特大学 Method for treating situation relevant to MASP-2 dependent complement activation
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (en) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 Liraglutide variant and conjugate thereof
US20140296147A1 (en) 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
WO2013126606A1 (en) * 2012-02-21 2013-08-29 Production Sciences, Inc. System and method for measuring well flow rate
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
ES2755104T3 (en) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
US20150330989A1 (en) 2012-11-15 2015-11-19 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
BR112016021629A2 (en) 2014-03-20 2018-07-10 Inflarx Gmbh c5a inhibitors for the treatment of viral pneumonia
KR102503319B1 (en) * 2014-06-12 2023-02-28 라 파마슈티컬스 인코포레이티드 Modulation of complement activity
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
CN107427482A (en) 2015-01-21 2017-12-01 帕西拉制药有限公司 Multivesicular liposomal formulation of tranexamic acid
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
RS64067B1 (en) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulators of complement activity
WO2018106859A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US20200282024A1 (en) 2017-09-11 2020-09-10 Ra Pharmaceuticals, Inc. Formulations for compound delivery
CN111683672A (en) 2017-12-04 2020-09-18 Ra制药公司 complement activity regulator
EP3934675A2 (en) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Zilucoplan as deep tissue penetrating c5 inhibitor
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Also Published As

Publication number Publication date
PT3250230T (en) 2021-12-07
CY1124761T1 (en) 2022-11-25
RS62630B9 (en) 2022-04-29
EP3250230A1 (en) 2017-12-06
US10918691B2 (en) 2021-02-16
HUE056613T2 (en) 2022-02-28
US20190307835A1 (en) 2019-10-10
HK1246672A1 (en) 2018-09-14
ES2900998T3 (en) 2022-03-21
US20200155639A1 (en) 2020-05-21
US20180193408A1 (en) 2018-07-12
EP3988110A1 (en) 2022-04-27
US9937222B2 (en) 2018-04-10
US20210283212A1 (en) 2021-09-16
US20240156896A1 (en) 2024-05-16
US20180021402A1 (en) 2018-01-25
JP6640229B2 (en) 2020-02-05
JP6915034B2 (en) 2021-08-04
PL3250230T3 (en) 2022-02-14
US10588936B2 (en) 2020-03-17
EP3250230B9 (en) 2022-02-23
US12239684B2 (en) 2025-03-04
SI3250230T1 (en) 2022-01-31
RS62630B1 (en) 2021-12-31
LT3250230T (en) 2021-12-27
US10328115B2 (en) 2019-06-25
JP2018509388A (en) 2018-04-05
EP3250230B1 (en) 2021-11-10
JP2020073526A (en) 2020-05-14
WO2016123371A1 (en) 2016-08-04
US11707503B2 (en) 2023-07-25
SMT202100688T1 (en) 2022-01-10
EP3250230A4 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
HRP20211824T1 (en) Modulators of complement activity
MX2023012450A (en) Esketamine for the treatment of depression.
MX2021000071A (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease.
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
MX2021004821A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy.
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
BR112017023904A2 (en) mono- or disubstituted indole derivatives as inhibitors of dengue viral replication
MX2024002360A (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS.
EA201992329A1 (en) SUBSTITUTED INDOLINE DERIVATIVES AS MONEY VIRUS REPLICATION INHIBITORS
EA201791903A1 (en) β-D-2'-deoxy-2'-α-fluoro-2'-β-C-substituted
BR112018069601A2 (en) substituted indoline derivatives as dengue viral replication inhibitors
EA201992334A1 (en) SUBSTITUTED INDOLINE DERIVATIVES AS MONEY VIRUS REPLICATION INHIBITORS
BR112017015123A2 (en) indole derivatives as dengue viral replication inhibitors
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
EP4324454A3 (en) Cross-linking agents and associated methods
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
MX2020001164A (en) Composition for use in the prevention and/or treatment of oncologic treatment induced orogastrointestinal mucositis.
MX2021011289A (en) Compositions comprising pkm2 modulators and methods of treatment using the same.
BR112019004791A2 (en) multiple sclerosis treatment with chs-131
MX2016006657A (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis.
MX2023012415A (en) Methods of using dantrolene to treat nerve agent exposure.
BR112017002449A2 (en) treatment of symptoms associated with androgen deprivation therapy